Biomedical or Dental Material
Sanofi Acquires Exclusive Rights to Develop and Commercialize Cytokinetics’ Aficamten in Greater China
Sanofi, Cytokinetics, Aficamten, Greater China, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor, Pharmaceutical Deal
Lonza Expands Gelatin Capsule Production in India and China Amid Plans to Exit Capsules Business
Lonza, Capsules & Health Ingredients, Gelatin Capsules, India, China, Expansion, Exit Strategy
FDA Confirms Tirzepatide Availability, Compounders Express Concerns, While Semaglutide Shortage Persists
FDA, tirzepatide, semaglutide, GLP-1 drug shortage, compounders, pharmaceutical availability
Keros Therapeutics Faces Major Setback as PAH Trial Dosing Suspended Over Safety Concerns
Keros Therapeutics, PAH trial, dosing suspension, safety concerns, pulmonary arterial hypertension, cibotercept (KER-012), Phase II TROPOS trial
Lonza Announces Strategic Shift to Focus on CDMO Business, Exits Capsules & Health Ingredients
Lonza, CDMO, Capsules & Health Ingredients, Restructure, One Lonza Strategy
Novo Nordisk Invests $409M in New Quality Control Lab in Denmark
Novo Nordisk, quality control lab, Denmark, pharmaceutical investment, biotechnology
GSK Invests $546M in Rgenta’s RNA Modulation Technology for Cancer and Other Diseases
GSK, Rgenta, RNA modulation, cancer treatment, pharmaceutical investment
Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals for $558.4 Million
Coherus BioSciences, Udenyca, Intas Pharmaceuticals, pegfilgrastim-cbqv, immuno-oncology, pharmaceutical deal
Takeda Acquires Rights to Rival BMS’ Reblozyl with $200M Upfront Payment to Keros
Takeda, Keros Therapeutics, Bristol-Myers Squibb, Reblozyl, Cancer Treatment, Pharmaceutical Deal
Novartis Invests $1 Billion in PTC’s Huntington’s Disease Program
Novartis, PTC, Huntington’s disease, pharmaceutical investment, gene therapy